DFTX
Definium Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$38.09
+0.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 527.0K | 3.2M | — |
| Gross Profit | — | — | (527.0K) | (3.2M) | — |
| Operating Expenses | |||||
| R&D Expense | 154.6M | 117.7M | 65.3M | 49.0M | 36.2M |
| SG&A Expense | 72.9M | 48.6M | 38.6M | 41.7M | 30.2M |
| General & Admin Expense | 72.9M | 48.6M | 38.6M | 41.7M | 30.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (527.0K) | — | — |
| Total Operating Expenses | 227.5M | 166.3M | 103.4M | 90.7M | 66.3M |
| Cost and Expenses | 227.5M | 166.3M | 103.9M | 93.9M | 66.3M |
| Operating Income (EBIT) | (227.5M) | (166.3M) | (103.9M) | (93.9M) | (66.3M) |
| Non-Operating | |||||
| Interest Income | 12.8M | 11.0M | 11.6M | 5.6M | 1.5M |
| Interest Expense | 13.4M | 5.5M | 2.3M | 920.0K | 1.5M |
| Net Interest Income | (651.0K) | 5.5M | 9.3M | 4.7M | — |
| Other Non-Op Income/Expense | (126.2M) | (17.5M) | (4.8M) | (1.9M) | 9.5M |
| Non-Operating Income (excl Interest) | 112.8M | 12.0M | 2.5M | 1.9M | (11.0M) |
| EBT (Pre-Tax Income) | (353.8M) | (183.8M) | (108.7M) | (95.7M) | (56.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (353.8M) | (183.8M) | (108.7M) | (95.7M) | (56.8M) |
| Earnings from Cont. Ops | (353.8M) | (183.8M) | (108.7M) | (95.7M) | (56.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (353.8M) | (183.8M) | (108.7M) | (95.7M) | (56.8M) |
| Per Share | |||||
| Basic EPS | ($3.44) | ($2.06) | ($1.54) | ($2.44) | ($1.53) |
| Diluted EPS | ($3.43) | ($2.06) | ($0.15) | ($2.44) | ($1.53) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 110.7M | 89.3M | 70.5M | 39.2M | 30.9M |
| Diluted Shares Outstanding | 110.7M | 89.3M | 704.6M | 39.2M | 30.9M |
| Profitability Metrics | |||||
| EBITDA | (339.7M) | (178.3M) | (105.9M) | (92.6M) | (52.1M) |
| D&A | 637.8K | — | 527.0K | 3.2M | 3.2M |
| EBIT | (340.3M) | (178.3M) | (106.4M) | (95.7M) | (55.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026